Tardive dyskinesia: Pathophysiology and animal models

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 4, 2000, Pages 5-9

  Casey, Daniel E ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; THIORIDAZINE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE ASSOCIATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR SENSITIVITY; TARDIVE DYSKINESIA;

AGE FACTORS; ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; GAMMA-AMINOBUTYRIC ACID; HALOPERIDOL; HUMANS; MASTICATION; NEUROTOXICITY SYNDROMES; PSYCHOTIC DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE;

EID: 0034061290     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Casey DE. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1497-1502
2. Casey DE. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Hirsch S, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell; 1995:546-565
3. Kane JM, Jeste DV, Barnes TRE, et al. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992
4. Casey DE. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J Clin Psychiatry 1985;46(4, sec 2):42-47
5. Casey DE. Tardive dyskinesia: animal models. Psychopharmacol Bull 1984;20:376-379
6. Gunne LM, Barany S. Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology (Berl) 1976;50:237-240
7. Rupniak NMJ, Jenner P, Marsden CD. Cholinergic manipulation of perioral behavior induced by chronic neuroleptic administration to rats. Psychopharmacology (Berl) 1983;79:226-230
8. Gunne LM, Andersson U, Bondesson U, et al. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 1986;25:897-901
9. Johansson P, Casey DE, Gunne LM. Dose-dependent increases in rat spontaneous chewing rates during long-term administration of haloperidol but not clozapine. Psychopharmacol Bull 1986;22:1017-1019
10. Gao X, Sakai K, Tamminga CA. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Neuropsychopharmacology 1998;19:428-433
11. Tamminga CA, Dale JM, Goodman L, et al. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl) 1990;102:474-478
12. Klawans HL, Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm 1972;33:235-246
13. Tarsy D, Baldessarini RJ. Pharmacologically induced behavioral supersensitivity to apomorphine. Nature 1973;245:262-263
14. Waddington JL, Cross AJ, Gamble SJ, et al. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 1983;220:530-532
15. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989;99:S47-S53
16. Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 1998;59(suppl 3):31-37
17. Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-330
18. Beasley CM Jr, Dellva M, Tamura RN, et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30
19. Gunne LM, Haggstrom JE, Sjoquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984;309:347-349
20. Crow TJ, Cross AJ Johnstone EC, et al. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? are they associated with changes in dopamine receptors? J Clin Psychopharmacol 1982;2:336-340
21. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719
22. Fibiger HC, Lloyd KG. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 1984;7:462-464
23. Lohr JB. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry 1991;48:1097-1106
24. Adler LA, Edson R, Lavori P, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998;43:868-872
25. Jeste DV, Lohr JB, Eastham JH, et al. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res 1998;32:201-214
26. Hoffman WF, Casey DE. Computed tomographic evaluation of patients with tardive dyskinesia. Schizophr Res 1991;5:1-12
27. Chakos MH, Lieberman JA, Bilder RM, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994;151:1430-1436
28. Corson PW, Nopoulos P, Miller DD, et al. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 1999;156:1200-1204
29. Meshul CK, Janowsky A, Casey DE, et al. Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology (Berl) 1992;106: 45-52
30. Richardson MA, Suckow R, Whittaker R, et al. The plasma phenylalanine/large neutral amino acid ratio: a risk factor for tardive dyskinesia. Psychopharmacol Bull 1989;25:47-51
31. Ganzini L, Heintz R, Hoffman W, et al. Prevalence of tardive dyskinesia in neuroleptic treated diabetics. Arch Gen Psychiatry 1991;48:259-263
32. Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh, Scotland: E & S Livingstone; 1919
33. Bleuler E. Dementia Praecox or the Group of Schizophrenias. New York, NY: International Universities Press; 1950
34. Fenn DS, Moussaoui D, Hoffman WF, et al. Abnormal movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology (Berl) 1996;123:206-210